A Phase I Investigator Sponsored Trial of Selinexor (KPT-330), a Selective Inhibitor of Nuclear Export / SINE™ Compound and Ifosfamide, Carboplatin, Etoposide (ICE) in Patients With Relapsed or Refractory Peripheral T-cell Lymphoma
Phase of Trial: Phase I
Latest Information Update: 04 Apr 2018
At a glance
- Drugs Selinexor (Primary) ; Carboplatin; Etoposide; Ifosfamide
- Indications Peripheral T-cell lymphoma
- Focus Adverse reactions
- 31 Aug 2018 Biomarkers information updated
- 27 Mar 2018 Planned End Date changed from 1 Apr 2018 to 1 Apr 2019.
- 27 Mar 2018 Planned primary completion date changed from 1 Feb 2018 to 1 Feb 2019.